Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization
- CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data
- Xeltis advances ahead of schedule to commercialization
- aXess™ reduces the need for vascular access interventions enabling more streamlined kidney care delivery
EINDHOVEN, The Netherlands – 21 April, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has received the CE mark for aXess™, its restorative vascular access conduit for hemodialysis treatment, marking a significant regulatory milestone and the Company’s transition from a clinical‑stage to a commercial‑stage organization.
